Sanofi (SNY) reports FDA expanded indication for Soliqua 100/33
Tweet Send to a Friend
The U.S. Food and Drug Administration (FDA) has approved the expanded use of Soliqua® 100/33 (insulin glargine and lixisenatide injection) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
